← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Therasource, Llc
Roslyn, NY
$23,076,404
Total funding
25
Grants
Funding over time
peak $2M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$23,076,404 · 25
By mechanism
R44$16,960,088 · 9
R43$4,333,659 · 13
N01$1,249,317 · 1
R41$333,340 · 1
N43$200,000 · 1
Investigators at Therasource, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Human Ghrelin as an Effective Mitigator of Acute Radiation Injury$991,403
R44 · FY2017 · AI
rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock$986,433
R44 · FY2021 · HL
Human Ghrelin as an Effective Mitigator of Acute Radiation Injury$982,469
R44 · FY2016 · AI
Human Ghrelin as an Effective Mitigator of Acute Radiation Injury$982,276
R44 · FY2018 · AI
A Novel Recombinant Protein for Mitigating Acute Radiation Injury$974,383
R44 · FY2020 · AI
A Novel Recombinant Protein for Mitigating Acute Radiation Injury$974,383
R44 · FY2022 · AI
A Novel Recombinant Protein for Mitigating Acute Radiation Injury$974,383
R44 · FY2021 · AI
rhMFG-E8 for Alcohol-induced Tissue Injury and Infections (TheraSource, LLC)$778,788
N01 · FY2014 · HD
Antagonism of Alpha2A-Adrenoceptor: A Novel Anti-Sepsis Therapy$713,482
R44 · FY2011 · AI
A Novel Therapy for Septic Shock$571,120
R44 · FY2011 · HL
Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly$540,425
R44 · FY2016 · AG
Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly$540,425
R44 · FY2017 · AG
A Novel Therapy for Septic Shock$528,088
R44 · FY2009 · HL
rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock$505,554
R44 · FY2019 · HL
rhMFG-E8 as an Effective Adjuvant Therapy for Hemorrhagic Shock$505,554
R44 · FY2020 · HL
A Novel Therapy for Septic Shock$500,425
R44 · FY2010 · HL
A Novel Resuscitation for Hemorrhagic Shock: AM/AMBP-1$499,987
R44 · FY2009 · HL
A Novel Resuscitation for Hemorrhagic Shock: AM/AMBP-1$499,641
R44 · FY2007 · HL
Preclinical Testing of Human Ghrelin and Growth Hormone for Sepsis in the Elderly$486,925
R44 · FY2018 · AG
A Novel Resuscitation for Hemorrhagic Shock: AM/AMBP-1$485,425
R44 · FY2008 · HL